| Date | Action | Conf | Host / episode | Summary | 7d | 30d | 90d |
|---|---|---|---|---|---|---|---|
| 2026-09-22 | WATCH | MEDIUM | Rob Black Show Afternoon podcast 9-22-26 |
Moderna rose about 5.5% to fresh multiyear highs while Rob expressed a favorable long-term healthcare outlook. [audio] | +11.4% | — | — |
| 2026-09-21 | WATCH | MEDIUM | Rob Black Show Afternoon podcast 9-21-26 |
Rob highlighted upcoming cancer-vaccine trial presentations with Merck and the opportunity to diversify beyond COVID vaccines, while emphasizing clinical and regulatory risks. [audio] | +14.1% | — | — |
| 2026-09-17 | WATCH | MEDIUM | Rob Black Show Afternoon podcast 9-17-26 |
Rob highlighted Moderna's personalized melanoma-vaccine results while warning about declining COVID revenue. [audio] | +23.2% | — | — |
| 2026-09-01 | MENTIONED | MEDIUM | Rob Black Show Afternoon podcast 9-1-26 |
Rose 9.9% as positive melanoma vaccine results continue to trickle in. [audio] | -9.0% | — | — |
| 2026-08-26 | BUY | MEDIUM | Rob Black Show Afternoon podcast 8-26-26 |
Down 5.7% but Rob called it very speculative with home run potential, devoting a segment to the personalized mRNA cancer vaccine that in Phase 3 with Merck's Keytruda kept patients cancer-free longer than Keytruda alone. [audio] | +0.8% | +32.9% | — |
| 2026-08-26 | MENTIONED | LOW | Rob Black Show Inflation Remains Elevated |
Moderna continues a volatile stretch after last week's triple-digit surge and is weighing on the healthcare sector; also credited via Dolly Parton's Vanderbilt donation that helped fund COVID research. [audio] | +0.8% | +32.9% | — |
| 2026-08-25 | BUY | MEDIUM | Rob Black Show Afternoon podcast 8-25-26 |
Up 14.3% as the personalized melanoma cancer vaccine data keeps working, and Rob says he is speculative but genuinely interested if approvals extend to lung and thyroid cancer. [audio] | -2.9% | +22.7% | — |
| 2026-08-20 | WATCH | HIGH | Rob Black Show Afternoon podcast 8-20-26 |
Rob is keeping a close eye on Moderna, saying FDA approval of its personalized mRNA melanoma vaccine would be a major catalyst after a huge up day followed by a big loss. [audio] | +7.1% | +15.5% | — |
| 2026-08-20 | BUY | HIGH | Rob Black Show Markets Drop Hurt By Rising Treasury Yields |
Moderna surged 90% on phase three results for its personalized mRNA melanoma vaccine with Merck, which Rob called a potential game changer with $2.5 billion in eventual melanoma sales. [audio] | +7.1% | +15.5% | — |
| 2026-08-19 | BUY | HIGH | Rob Black Show Afternoon podcast 8-19-26 |
Moderna finished up 176% after phase three results for its personalized mRNA melanoma vaccine with Merck, which Rob called potentially one of the biggest breakthroughs in medical history. [audio] | -14.2% | -11.7% | — |
| 2026-08-19 | WATCH | HIGH | Rob Black Show Stock Market Is Shrugging Off Geopolitical Risks |
Moderna surged 90% on promising late-stage melanoma cancer vaccine results developed with Merck; Rob called it very speculative but very interesting science. [audio] | -14.2% | -11.7% | — |
| 2026-06-30 | BUY | MEDIUM | Rob Black Show Markets Rise To Close Out First Half Of 2026 |
Moderna rising to best level since September 2024; host likes company but prefers to own it in S&P 500. [audio] | +13.9% | -17.3% | +181.7% |
| 2026-06-02 | BUY | HIGH | Rob Black Show Markets Start The Day With Highs |
Host recommends buying ahead of earnings due to strong mRNA vaccine sales. [audio] | +4.6% | +74.8% | +207.5% |
| 2026-05-26 | MENTIONED | HIGH | Rob Black Show Hope Over A Potential Deal With Iran |
Micron is soaring today as UBS more than triples its price target to $1,625. [audio] | -3.0% | +27.0% | +195.3% |
| 2026-05-18 | MENTIONED | LOW | Rob Black Show Big Week With Nvidia Earnings |
Moderna is mentioned in the context of AI and biotech investments. [audio] | -2.6% | +28.5% | +31.6% |
| 2026-05-11 | MENTIONED | LOW | Rob Black Show Fresh Record Bolstered By Key Tech Stocks |
Noted as a big mover up 5.2% due to Hantavirus vaccine research news. [audio] | -9.0% | -13.0% | +11.9% |
| 2026-05-08 | MENTIONED | LOW | Rob Black Show Good Year In The Stock Market So Far |
Discussed in the context of earnings and AI partnerships. [audio] | -9.8% | -12.7% | -0.9% |